# Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia

> **NCT07429461** · EARLY_PHASE1 · RECRUITING · sponsor: **Zhejiang University** · enrollment: 16 (estimated)

## Conditions studied

- B-Cell Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** SYNCAR-100 Injection

## Key facts

- **NCT ID:** NCT07429461
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-28
- **Primary completion:** 2027-12-31
- **Final completion:** 2041-12-31
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07429461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07429461, "Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07429461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*